MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

Modern Pathology

Volumn 26, Issue 12, 2013, Pages 1632-1641

  Ha, Sang Y ^a   Lee, Jeeyun ^a   Kang, So Y ^a   Do, In Gu ^a   Ahn, Soomin ^a   Park, Joon O ^a   Kang, Won K ^a   Choi, Min Gew ^a   Sohn, Tae S ^a   Bae, Jae M ^a   Kim, Sung ^a   Kim, Minji ^a   Kim, Seonwoo ^a   Park, Cheol K ^a   Ignatius Ou, Sai Hong ^b   Kim, Kyoung Mee ^a  

^a Samsung Medical Center   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene amplification; Immunohistochemistry; MET; Overexpression; Prognosis

Indexed keywords

MESSENGER RNA; SCATTER FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERINEURAL INVASION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CARCINOMA;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MET; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84889095358     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.108     Document Type: Article

References (33)

1. Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-2214.
2. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
3. Graziano F, Galluccio N, Lorenzini P, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011;29:4789-4795.
4. Yap TA, Olmos D, Brunetto AT, et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011;29:1271-1279.
5. Park WS, Oh RR, Kim YS, et al. Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. APMIS 2000;108:195-200. (Pubitemid 30158999)
6. Hara T, Ooi A, Kobayashi M, et al. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 1998;78:1143-1153. (Pubitemid 28440830)
7. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-1902. (Pubitemid 29202761)
8. Tsugawa K, Yonemura Y, Hirono Y, et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 1998;55:475-481. (Pubitemid 28396062)
9. Seruca R, Suijkerbuijk RF, Gartner F, et al. Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer. Cancer Genet Cytogenet 1995;82:140-145.
10. Nessling M, Solinas-Toldo S, Wilgenbus KK, et al. Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes Cancer 1998;23:307-316. (Pubitemid 28507370)
11. Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992;189:227-232. (Pubitemid 23030031)
12. Tsujimoto H, Sugihara H, Hagiwara A, et al. Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 1997;431:383-389. (Pubitemid 27519371)
13. Sakakura C, Mori T, Sakabe T, et al. Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer 1999;24: 299-305. (Pubitemid 29115867)
14. Lee J, Seo JW, Jun HJ, et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011;25:1517-1524.
15. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006;103: 2316-2321. (Pubitemid 43271667)
16. Lee HE, Kim MA, Lee HS, et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 2012;107:325-333.
17. Amemiya H, Kono K, Itakura J, et al. c-Met expression in gastric cancer with liver metastasis. Oncology 2002;63:286-296. (Pubitemid 36151324)
18. Drebber U, Baldus SE, Nolden B, et al. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 2008;19:1477-1483.
19. Heideman DA, Snijders PJ, Bloemena E, et al. Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma. J Pathol 2001;194:428-435. (Pubitemid 32782667)
20. Huang TJ, Wang JY, Lin SR, et al. Overexpression of the c-met protooncogene in human gastric carcinoma-correlation to clinical features. Acta Oncol 2001;40: 638-643.
21. Wu CW, Li AF, Chi CW, et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 1998;5:817-822. (Pubitemid 28270673)
22. Yonemura Y, Kaji M, Hirono Y, et al. Correlation between overexpression of c-met gene and the progression of gastric cancer. Int J Oncol 1996;8:555-560. (Pubitemid 26082173)
23. Toiyama Y, Yasuda H, Saigusa S, et al. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 2011;130:2912-2921.
24. Janjigian YY, Tang LH, Coit DG, et al. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 2011;20: 1021-1027.
25. Spigel DRET, Ramlau R, Daniel DB, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC, 2011 ASCO Annual Meeting: Chicago, IL, USA, 2011.
26. Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
27. Iveson TDR, Davidenko I, Tjulandin S, et al. Safety and efficacy of epirubicin, cisplatin, and capecitabine (ECX) plus rilotumumab (R) as first-line treatment for unresectable locally advanced (LA) or metastatic (M) gastric or esophagogastric junction (EGJ) adenocarcinoma, European Journal of Cancer. Stockholm, 2011.
28. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003;16:173-182. (Pubitemid 36245750)
29. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
30. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. (Pubitemid 351724903)
31. Cho EY, Choi YL, Han JJ, et al. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathol Int 2008;58:17-25. (Pubitemid 350198303)
32. Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25:637-650.
33. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803-4810.